Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer

Wook Kim Dong, Yu Shyr, Heidi Chen, Wallace Akerley, David H. Johnson, Hak Choy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: Although concurrent chemoradiotherapy can now achieve demonstrated long-term survival in patients with locally advanced non-small-cell lung cancer (LANSCLC), it is difficult to predict which patients will benefit most from this therapeutic approach. Studies have suggested that local control, and the response to therapy, may be linked to improved survival; however, detailed analysis of the impact of tumor response to chemoradiotherapy on survival has not been thoroughly reported. Therefore, we sought to determine the impact of the response rate on survival for patients who were treated with combined modality therapy for LANSCLC. Methods and Materials: We reviewed the data from 116 patients enrolled between 1994 and 1997 in three trials investigating paclitaxel-based concurrent chemoradiotherapy for LANSCLC. Tumor size measurements were assessed immediately before and 2 months after completion of combined modality therapy to determine the response and to calculate the percentage of decrease in tumor size. Results: Patients with a response (complete or partial) had an improved 4-year overall survival rate compared with patients with no response (stable or progressive disease; 21.1% vs. 3.3%, p <0.0001) in the 109 assessable patients. Progression-free survival also improved significantly with response. An analysis of the percentage of decrease in tumor size vs. survival was performed (n = 74) using Cox proportion model analysis. After combined modality therapy, a 20%, 40%, 60%, 80%, and 100% decrease in tumor size conferred a 39%, 63%, 78%, 86%, and 92% reduction in risk of death compared with a 0% decrease in tumor size (p <0.0001). Conclusion: The response by conventional response criteria correlated strongly with improved overall survival and progression-free survival and an increasing percentage of decrease in tumor size resulted in a reduction in the risk of death. Additional investigation of the degree of response as a factor predictive of improved therapeutic efficacy, translating into improved survival, is warranted.

Original languageEnglish (US)
Pages (from-to)1029-1036
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume63
Issue number4
DOIs
StatePublished - Nov 15 2005

Fingerprint

Combined Modality Therapy
Non-Small Cell Lung Carcinoma
lungs
therapy
cancer
Survival
tumors
Chemoradiotherapy
Neoplasms
Risk Reduction Behavior
Disease-Free Survival
Survival Rate
death
progressions
Paclitaxel
Proportional Hazards Models
translating
Therapeutics
proportion

Keywords

  • Chemoradiation
  • Combined modality therapy
  • Non-small-cell lung cancer
  • Paclitaxel
  • Phase II
  • Response

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. / Dong, Wook Kim; Shyr, Yu; Chen, Heidi; Akerley, Wallace; Johnson, David H.; Choy, Hak.

In: International Journal of Radiation Oncology Biology Physics, Vol. 63, No. 4, 15.11.2005, p. 1029-1036.

Research output: Contribution to journalArticle

@article{2bc430b6d8ac4a438e3c7c0f03e3013a,
title = "Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer",
abstract = "Purpose: Although concurrent chemoradiotherapy can now achieve demonstrated long-term survival in patients with locally advanced non-small-cell lung cancer (LANSCLC), it is difficult to predict which patients will benefit most from this therapeutic approach. Studies have suggested that local control, and the response to therapy, may be linked to improved survival; however, detailed analysis of the impact of tumor response to chemoradiotherapy on survival has not been thoroughly reported. Therefore, we sought to determine the impact of the response rate on survival for patients who were treated with combined modality therapy for LANSCLC. Methods and Materials: We reviewed the data from 116 patients enrolled between 1994 and 1997 in three trials investigating paclitaxel-based concurrent chemoradiotherapy for LANSCLC. Tumor size measurements were assessed immediately before and 2 months after completion of combined modality therapy to determine the response and to calculate the percentage of decrease in tumor size. Results: Patients with a response (complete or partial) had an improved 4-year overall survival rate compared with patients with no response (stable or progressive disease; 21.1{\%} vs. 3.3{\%}, p <0.0001) in the 109 assessable patients. Progression-free survival also improved significantly with response. An analysis of the percentage of decrease in tumor size vs. survival was performed (n = 74) using Cox proportion model analysis. After combined modality therapy, a 20{\%}, 40{\%}, 60{\%}, 80{\%}, and 100{\%} decrease in tumor size conferred a 39{\%}, 63{\%}, 78{\%}, 86{\%}, and 92{\%} reduction in risk of death compared with a 0{\%} decrease in tumor size (p <0.0001). Conclusion: The response by conventional response criteria correlated strongly with improved overall survival and progression-free survival and an increasing percentage of decrease in tumor size resulted in a reduction in the risk of death. Additional investigation of the degree of response as a factor predictive of improved therapeutic efficacy, translating into improved survival, is warranted.",
keywords = "Chemoradiation, Combined modality therapy, Non-small-cell lung cancer, Paclitaxel, Phase II, Response",
author = "Dong, {Wook Kim} and Yu Shyr and Heidi Chen and Wallace Akerley and Johnson, {David H.} and Hak Choy",
year = "2005",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2005.03.055",
language = "English (US)",
volume = "63",
pages = "1029--1036",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer

AU - Dong, Wook Kim

AU - Shyr, Yu

AU - Chen, Heidi

AU - Akerley, Wallace

AU - Johnson, David H.

AU - Choy, Hak

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Purpose: Although concurrent chemoradiotherapy can now achieve demonstrated long-term survival in patients with locally advanced non-small-cell lung cancer (LANSCLC), it is difficult to predict which patients will benefit most from this therapeutic approach. Studies have suggested that local control, and the response to therapy, may be linked to improved survival; however, detailed analysis of the impact of tumor response to chemoradiotherapy on survival has not been thoroughly reported. Therefore, we sought to determine the impact of the response rate on survival for patients who were treated with combined modality therapy for LANSCLC. Methods and Materials: We reviewed the data from 116 patients enrolled between 1994 and 1997 in three trials investigating paclitaxel-based concurrent chemoradiotherapy for LANSCLC. Tumor size measurements were assessed immediately before and 2 months after completion of combined modality therapy to determine the response and to calculate the percentage of decrease in tumor size. Results: Patients with a response (complete or partial) had an improved 4-year overall survival rate compared with patients with no response (stable or progressive disease; 21.1% vs. 3.3%, p <0.0001) in the 109 assessable patients. Progression-free survival also improved significantly with response. An analysis of the percentage of decrease in tumor size vs. survival was performed (n = 74) using Cox proportion model analysis. After combined modality therapy, a 20%, 40%, 60%, 80%, and 100% decrease in tumor size conferred a 39%, 63%, 78%, 86%, and 92% reduction in risk of death compared with a 0% decrease in tumor size (p <0.0001). Conclusion: The response by conventional response criteria correlated strongly with improved overall survival and progression-free survival and an increasing percentage of decrease in tumor size resulted in a reduction in the risk of death. Additional investigation of the degree of response as a factor predictive of improved therapeutic efficacy, translating into improved survival, is warranted.

AB - Purpose: Although concurrent chemoradiotherapy can now achieve demonstrated long-term survival in patients with locally advanced non-small-cell lung cancer (LANSCLC), it is difficult to predict which patients will benefit most from this therapeutic approach. Studies have suggested that local control, and the response to therapy, may be linked to improved survival; however, detailed analysis of the impact of tumor response to chemoradiotherapy on survival has not been thoroughly reported. Therefore, we sought to determine the impact of the response rate on survival for patients who were treated with combined modality therapy for LANSCLC. Methods and Materials: We reviewed the data from 116 patients enrolled between 1994 and 1997 in three trials investigating paclitaxel-based concurrent chemoradiotherapy for LANSCLC. Tumor size measurements were assessed immediately before and 2 months after completion of combined modality therapy to determine the response and to calculate the percentage of decrease in tumor size. Results: Patients with a response (complete or partial) had an improved 4-year overall survival rate compared with patients with no response (stable or progressive disease; 21.1% vs. 3.3%, p <0.0001) in the 109 assessable patients. Progression-free survival also improved significantly with response. An analysis of the percentage of decrease in tumor size vs. survival was performed (n = 74) using Cox proportion model analysis. After combined modality therapy, a 20%, 40%, 60%, 80%, and 100% decrease in tumor size conferred a 39%, 63%, 78%, 86%, and 92% reduction in risk of death compared with a 0% decrease in tumor size (p <0.0001). Conclusion: The response by conventional response criteria correlated strongly with improved overall survival and progression-free survival and an increasing percentage of decrease in tumor size resulted in a reduction in the risk of death. Additional investigation of the degree of response as a factor predictive of improved therapeutic efficacy, translating into improved survival, is warranted.

KW - Chemoradiation

KW - Combined modality therapy

KW - Non-small-cell lung cancer

KW - Paclitaxel

KW - Phase II

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=27144438654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144438654&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.03.055

DO - 10.1016/j.ijrobp.2005.03.055

M3 - Article

VL - 63

SP - 1029

EP - 1036

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -